Tuesday Health Report: New AstraZeneca Drug May Be First to Reduce COPD Symptoms, FDA Approval Sought
AstraZeneca said the first-in-class antibody reduced moderate and severe flare-ups by up to 34% in late-stage trials.
- Results presented Tuesday at the European Respiratory Society Congress show AstraZeneca's drug tozorakimab demonstrated promise in reducing COPD symptoms during late-stage clinical trials.
- Nearly 16 million U.S. adults suffer from COPD, a leading cause of death often linked to tobacco, though one in four patients have never smoked, the CDC reports.
- Patients receiving 300 milligrams of tozorakimab every four weeks saw symptom reductions ranging from 29% to 34%, according to data from two separate AstraZeneca-sponsored clinical trials.
- The Food and Drug Administration accepted tozorakimab for priority review as an add-on maintenance treatment for adults, marking the first biologic drug for COPD management.
- Ongoing investigations are evaluating tozorakimab's potential application for asthma and lower respiratory tract disease, expanding on its development as a monoclonal antibody targeting inflammation.
16 Articles
16 Articles
Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By Nancy Lapid Sept 9 (Reuters) - Today we feature data from studies being presented at the ongoing European Respiratory Society Co...
New drug shows promise in reducing COPD symptoms in smokers, clinical trials show - Regional Media News
(NEW YORK) - A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former and current smokers, according to results from late-stage clinical trials. The medication, called tozorakimab and developed by AstraZeneca, is the first biologic drug [...]
MyCentralOregon.com
New drug shows promise in reducing COPD symptoms in smokers, clinical trials show
A healthcare professional examines a chest X-ray displayed on a tablet. (Getty Images/Tom Werner) (NEW YORK) — A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former and
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show COPD is one of the top 10 leading cause of death in the U.S., the CDC says. A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former…
Coverage Details
Bias Distribution
- 89% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
